Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLEGORY
2023-504774-38-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Obinutuzumab + standard therapy with Placebo + standard therapy (2 arms). Primary endpoint: Proportion of participants who achieve SRI(4) at Week 52. Planned start Nov 2021; status: authorised.
02
Drugs
obinutuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-504774-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504774-38-00.